Medicine and Dentistry
Krukenberg Tumor
100%
Neoplasm
84%
Breast Cancer
76%
Ovarian Cancer
50%
Immunohistochemistry
32%
Prognostic Factor
30%
Uterine Cancer
30%
Messenger RNA
30%
In Vitro
28%
Protein Expression
25%
Hazard Ratio
23%
Biological Marker
21%
Carcinoma
21%
Colorectal Carcinoma
21%
Endometrium Carcinoma
21%
Overall Survival
20%
Cyclooxygenase 2
20%
Malignant Neoplasm
19%
Endometriosis
18%
Breast Carcinoma
18%
Estrogen Receptor
17%
Epidermal Growth Factor Receptor 2
16%
Metastatic Carcinoma
16%
Gamma Urogastrone
15%
Cancer Cell
15%
Hormone Receptor
15%
Biopsy Technique
14%
ELAV Like Protein 1
13%
Histone Deacetylase
13%
Melanoma
13%
In Situ Hybridization
12%
Receptor Expression
12%
Cell Proliferation
11%
Protein Kinase B
11%
Protein P53
11%
Pathologist
11%
Diseases
10%
Next Generation Sequencing
10%
Colon Carcinoma
10%
Endometrium
10%
Risk Stratification
10%
Tissue Microarray
10%
Lymph Node
9%
Epidermal Growth Factor Receptor
9%
Cancer Staging
9%
Gene Expression
9%
Primary Tumor
9%
Guanine Nucleotide Binding Protein
9%
Mammalian Target of Rapamycin
9%
Carisoprodol
9%
Keyphrases
Breast Cancer
60%
Ovarian Carcinoma
49%
Tumor
37%
Immunohistochemistry
34%
Ovarian Cancer
33%
Prognostic Impact
30%
Endometrial Cancer
30%
Human Epidermal Growth Factor Receptor 2 (HER2)
30%
Epithelial Ovarian Cancer
29%
Cyclooxygenase-2
27%
Overall Survival
27%
Triple-negative Breast Cancer
27%
Prognostic Factors
25%
Overexpression
25%
Protein Expression
23%
Endometriosis
23%
Carcinoma
22%
Expression Pattern
22%
Formalin-fixed Paraffin-embedded Tissue
20%
Hazard Ratio
19%
Polo-like Kinase 1 (PLK1)
18%
EndoPredict
18%
Programmed Death-ligand 1 (PD-L1)
18%
Ovarian Cancer Cells
17%
In Situ Hybridization
17%
Core Needle Biopsy
17%
MRNA Expression
16%
Colorectal Cancer
15%
Human Ovarian Carcinoma
15%
Hormone Receptor-positive
14%
Tumor Grade
14%
MRNA Level
14%
DNA Methylation (DNAm)
14%
Sporadic Colorectal Cancer
13%
PITX2
13%
Mammalian Target of Rapamycin (mTOR)
13%
GPER1
13%
Metastasis
13%
Tumor-infiltrating Lymphocytes
13%
Histone Deacetylase 1 (HDAC1)
12%
Quantitative PCR
12%
Cyclooxygenase-2 Expression
12%
Anthracyclines
12%
High Risk
12%
P53 Expression
11%
HER2 Status
11%
Distinct Subtypes
11%
Breast Cancer Patients
11%
Tissue Microarray
10%
Poor Prognosis
10%
